In both the HR+ HER2-low and HER2+ breast cancer groups in Part 2A of the trial, a greater proportion of patients who received the 4.0 mg/kg dose achieved a higher objective response (OR) than those who received 3.0 mg/kg. Here, ERBB2 is linked to breast carcinoma.